Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors

Prognostic value of FDG PET/CT in de novo stage IV breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors

Abstract Background De novo stage IV breast cancer presents a significant challenge due to its advanced nature and poor prognosis. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy have emerged as effective treatments for hormone receptor-positive HER2-negative breast...

Full description

Saved in:
Bibliographic Details
Main Authors: Wonseok Whi, Junghoon Shin, Ji-Yeon Kim, Hee Kyung Ahn, Yeon Hee Park, Jin Seok Ahn, Hyunjong Lee
Format: Article
Language:English
Published: BMC 2025-07-01
Series:Breast Cancer Research
Subjects:
De Novo stage IV breast cancer
FDG PET/CT
Cyclin-dependent kinase 4/6 inhibitor
Treatment response
Progression-free survival
Online Access:https://doi.org/10.1186/s13058-025-02087-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s13058-025-02087-6

Similar Items